ODT News and Press, Odonate Therapeutics Inc. From 12/23/20

Gainers: [[HTOOW]] +18.7%. [[SIF]] +16.4%. [[GBS]] +11.9%. [[ODT]] +10.9%. [[LAZRW]] +10.2%.Losers: [[ALT]] -10.5%. [[BFIIW]] -5.8%. [[BLU]] -4.2%. [[SCPL]] -4.0%. [[CATB]] -3.4%. For further details see: HTOOW, SIF, ALT and CATB among after-hours movers

NEW YORK, Dec. 17, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Jeffrey Vacirca to its ...

In a presentation at the 2020 San Antonio Breast Cancer Symposium, Odonate Therapeutics (ODT) announced positive Phase 3 clinical trial data for tesetaxel, its therapeutic candidate for metastatic breast cancer. The multinational, multicenter, randomized, Phase 3 study, conducted in North Ame...

Odonate Therapeutics ([[ODT]] -0.8%) announces positive results from a multinational, multicenter, randomized CONTESSA, Phase 3 trial evaluating lead candidate tesetaxel in metastatic breast cancer ((MBC)) patients.The study met the primary endpoint of improved Progre...

CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus the Approved Dose of Capecitabine Alone (Hazard Ratio=0.716; p=0.003) Median PFS Was 9.8 Months for Tesetaxel Plus a Reduced ...

vTv Therapeutics VTVT +128% as MacAndrews & Forbes buys 625K shares.Sonoma Pharmaceuticals SNOA +122% on Crown Laboratories partnership.FAT Brands FAT +60% on plan to merge with controlling shareholder Fog Cutter Capital.Lexicon Pharmaceuticals LXRX +38%...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced the initiation of Cohort 3 of CONTESSA TRIO, which will evaluate tesetaxel monothe...

Event will follow presentation of results of CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer, at the 2020 San Antonio Breast Cancer Symposium (SABCS) Featured speakers will include Lee Schwartzberg, M.D., FACP, Chief Medical Director, West Canc...

Odonate Therapeutics (ODT): Q3 GAAP EPS of -$0.93 in-line.Cash of $188.3MPress Release For further details see: Odonate Therapeutics EPS in-line

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and nine months ended September 30, 2020. As o...